Sun Pharma to buy Ranbaxy

Share this article:

Generics maker Sun Pharmaceutical is buying Daiichi Sankyo's generics firm Ranbaxy, which is based in India. Reuters reports that Daiichi Sankyo will get 0.8 Sun Pharma shares for each Ranbaxy share.

The news follows a slate of bad news about generics made in India, including the FDA banning products from four Ranbaxy sites. The FDA has defended generics made in India and has said it is working with the country's regulatory agency to bring up standards and manufacturing scrutiny.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.